Human Breast Cancer Anti-Estrogen Resistance Protein 1 (BCAR1) CLIA Kit

Background

BCAR1, also known as the Breast Cancer Anti-Estrogen Resistance 1 protein, is an important protein involved in the development of resistance to anti-estrogen therapies, such as tamoxifen, used in the treatment of estrogen receptor-positive breast cancer. BCAR1 plays a crucial role in cell signaling pathways that regulate cell survival, proliferation, and resistance to apoptosis. It is often upregulated in breast cancer cells that become resistant to estrogen receptor-targeted therapies. The protein interacts with several other signaling molecules involved in the regulation of cell motility and survival, contributing to the metastatic potential of breast cancer cells. Understanding BCAR1’s role in therapy resistance has significant implications for developing alternative therapeutic strategies for patients with estrogen receptor-positive breast cancer who develop resistance to current treatments.